

Medicare Private Plans Under Pressure to Improve

BY JOEL B. FINKELSTEIN
Contributing Writer

WASHINGTON — If competition drives prices down, why does the government pay private insurers more per patient than the Medicare program spends on the average beneficiary?

That is the question on the minds of a growing number of people, panelists said at a press briefing on health care costs sponsored by the Center for Studying Health System Change.

"A lot of folks are suffering from amnesia about this whole issue. In 2003, we passed something called the Medicare Modernization Act. ... It was about how are we going to solve the baby boomer problem, how are we going to bring Medicare costs under control," said Robert Laszewski, president of a health policy and marketplace consulting firm in Alexandria, Va.

At the time, the Republican-led Congress decided that the best way to bring costs under control was to encourage more Medicare beneficiaries to join private plans. So, depending on which type of plan they offer, managed care companies receive 10%-20% above what Medicare spends on the average beneficiary in the government-run, fee-for-service system. According to the philosophy behind the legislation, this would induce private insurers to offer managed Medicare products and enable them to offer more benefits to attract beneficiaries into the private plans.

It's 4 years later, Democrats are in power in Congress, and some are beginning to wonder what they are buying with the millions of extra dollars flowing to private insurers. Physician thought leaders, including those on the government's Medicare Physician Advisory Commission (MedPAC), have called for Congress to redirect those funds toward other priorities, such as fixing the sustainable growth rate formula.

However, it may be too early to pull the plug on this experiment in using private insurers to control costs, said Christine Arnold, who covers the managed care industry as a managing director at Morgan Stanley.

"The managed care companies that I speak to say that they can reduce medical costs 10% for a managed product versus an unmanaged product, but it takes 2-4 years," Ms. Arnold said.

It is not just in the Medicare program that the cost-saving techniques of managed care companies are being questioned.

Health savings accounts and other consumer-driven approaches are beginning to lose favor with the public. The number of U.S. workers who enrolled in consumer-directed plans grew by a meager 300,000 between 2005 and 2006, according to the Kaiser Family Foundation's annual survey of employer benefits.

A survey by America's Health Insurance Plans, a trade organization, seems to confirm that trend. After a couple of years in which enrollment in health savings account-affiliated, high-deductible plans doubled and then tripled, last year the number of people in the plans grew by less than a third.

Consumer-directed plans may be a good idea, but they're based on a false assumption that patients have the resources to make the right choices, said Douglas Simpson, the senior managed care analyst at Merrill Lynch & Co.

"We're incentivizing them with the benefit structure, but then we're really not giving them the tools to make better decisions. It's sort of like giving somebody \$100 to go out to dinner and then not putting the prices on the menu," Mr. Simpson said.

The cyclical nature of health care reform also is becoming more apparent, said Joshua Raskin, who covers the managed care industry as a senior vice president at Lehman Brothers Inc.

During the late 1980s and early 1990s, health care premiums were growing by double digits. Those increases resulted in a political backlash. At the time, it was Hillary Clinton's universal care plan that further popularized health maintenance organizations.

"HMOs had this huge period of proliferation, and you got the cost trending down in the mid-1990s to ... really low single digits," Mr. Raskin said.

Then the economy picked back up—and so did medical cost trends—and double-digit growth returned in the late 1990s into the early 2000s. Now, he said, the discussion is again focusing on "more government intervention. It's 2007 and 2008, and guess what: Hillary Clinton is back and so is universal health care." ■



Find a rhythm for relief

in Chronic Idiopathic Constipation

Predictable onset,* continued relief,† proven safety profile‡

- The ONLY agent approved for adults that includes those 65 years and older

Important Safety Information

- AMITIZA is indicated for the treatment of chronic idiopathic constipation in the adult population.
- AMITIZA should not be used in patients with a known hypersensitivity to any components of the formulation and in patients with a history of mechanical gastrointestinal obstruction. Patients with symptoms suggestive of mechanical gastrointestinal obstruction should be evaluated prior to initiating AMITIZA treatment.
- The safety of AMITIZA in pregnancy has not been evaluated in humans. In guinea pigs, lubiprostone has been shown to have the potential to cause fetal loss. AMITIZA should be used during pregnancy only if the benefit justifies the potential risk to the fetus. Women who could become pregnant should have a negative pregnancy test prior to beginning therapy with AMITIZA and should be capable of complying with effective contraceptive measures.
- AMITIZA should not be administered to patients that have severe diarrhea. Patients should be aware of the possible occurrence of diarrhea during treatment. If the diarrhea becomes severe, patients should consult their health professional.
- In clinical trials, the most common adverse event was nausea (31%). Other adverse events (≥5% of patients) included diarrhea (13%), headache (13%), abdominal distention (7%), abdominal pain (7%), flatulence (6%), sinusitis (5%) and vomiting (5%).

Relief is defined as ≥3 spontaneous bowel movements (SBMs) per week.

Please see Brief Summary of Prescribing Information on adjacent page.

*57%-63% of patients had a first SBM within 24 hours.

†In 4-week clinical trials. ‡Demonstrated in 6-month and 12-month safety studies.

Reference: 1. AMITIZA [package insert]. Bethesda, Md: Sucampo Pharmaceuticals, Inc.; 2006.

AMITIZA is a registered trademark of Sucampo Pharmaceuticals, Inc.

© 2007 Takeda Pharmaceuticals North America, Inc.

LUB-00789

Printed in U.S.A.

05/07

amitiza[®]
lubiprostone
Way to relief
www.amitiza.com